Shares of NuCana PLC (NASDAQ:NCNA) have earned an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the stock, Zacks Investment Research reports. Four investment analysts have rated the stock with a strong buy rating.
Brokerages have set a 12 month consensus price target of $26.50 for the company and are forecasting that the company will post ($0.14) EPS for the current quarter, according to Zacks. Zacks has also assigned NuCana an industry rank of 185 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research downgraded NuCana from a “buy” rating to a “hold” rating in a report on Tuesday, January 9th.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Sofinnova Management VIII L.L.C. boosted its holdings in NuCana by 600.0% in the fourth quarter. Sofinnova Management VIII L.L.C. now owns 4,666,666 shares of the company’s stock valued at $47,180,000 after purchasing an additional 4,000,000 shares in the last quarter. Alliancebernstein L.P. boosted its holdings in NuCana by 40.1% in the fourth quarter. Alliancebernstein L.P. now owns 910,358 shares of the company’s stock valued at $9,204,000 after purchasing an additional 260,358 shares in the last quarter. UBS Asset Management Americas Inc. boosted its holdings in NuCana by 4.5% in the fourth quarter. UBS Asset Management Americas Inc. now owns 464,600 shares of the company’s stock valued at $4,697,000 after purchasing an additional 19,800 shares in the last quarter. Alps Advisors Inc. acquired a new position in NuCana in the fourth quarter valued at approximately $357,000. Finally, Perceptive Advisors LLC acquired a new position in NuCana in the third quarter valued at approximately $3,674,000. 30.70% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Zacks: NuCana PLC (NCNA) Given Consensus Rating of “Strong Buy” by Analysts” was originally posted by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.tickerreport.com/banking-finance/3297599/zacks-nucana-plc-ncna-given-consensus-rating-of-strong-buy-by-analysts.html.
NuCana Company Profile
NuCana PLC is a clinical-stage biopharmaceutical company. The Company is focused on improving treatment outcomes for cancer patients by applying its phosphoramidate chemistry technology. The Company utilizes its ProTide technology to develop medicines to overcome cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.